Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 2/2013

01.03.2013 | Originalien

Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus

Effect on carotid intima-media thickness

verfasst von: T.A. Gheita, MD, H.A. Raafat, S. Sayed, H. El-Fishawy, M.M. Nasrallah, E. Abdel-Rasheed

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of the present study was to assess the effect of metabolic syndrome (MetS) and insulin resistance comorbidity on the carotid intima-media thickness (IMT) in systemic lupus erythematosus (SLE) patients and their relationship to clinical manifestations, disease activity, and damage.

Methods

The study included 92 SLE patients (mean age 30.18 ± 8.27 years) and 30 matched controls. Disease activity and damage were assessed by the SLEDAI and SLICC indices, respectively. The Health Assessment Questionnaire II (HAQII) and Quality of Life (QoL) index were evaluated in the patients. Levels of insulin, glucose, and creatinine and the lipid profile were measured in patients and controls. Insulin sensitivity was estimated using the homeostatic model assessment index (HOMA-B) for beta cell function and (HOMA-IR) for peripheral tissue insulin resistance. The carotid IMT was measured by ultrasonography.

Results

The SLE patients had high HOMA-IR and HOMA-B. The IMT was significantly increased (0.82± 0.29 mm) compared to the controls (0.45± 0.2 mm).The HOMA-IR, SLEDAI, SLICC, HAQII, and IMT were significantly higher and the QoL lower in those with MetS (n = 34) compared to those without (n = 58), while the HOMAB was comparable. There was a significant correlation between the IMT and the SLEDAI, SLICC, and WHR.

Conclusion

Insulin sensitivity and IMT are altered in SLE patients, especially those with MetS comorbidity with an associated increase in disease activity and damage. Effective management of MetS would help control SLE activity, damage, and the future development of cardiovascular events especially in the absence of symptoms of cardiovascular disease.
Literatur
1.
Zurück zum Zitat Mok CC, Wong RW, Lai KN (2003) Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62:799–804PubMedCrossRef Mok CC, Wong RW, Lai KN (2003) Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62:799–804PubMedCrossRef
2.
Zurück zum Zitat Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82(5):299–308 Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82(5):299–308
3.
Zurück zum Zitat Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406PubMedCrossRef Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406PubMedCrossRef
4.
Zurück zum Zitat Liese AD, Mayer-Davis EJ, Haffner SM (1998) Development of the multiple metabolic syndrome. An epidemiologic perspective. Epidemiol Rev 20:157–172PubMedCrossRef Liese AD, Mayer-Davis EJ, Haffner SM (1998) Development of the multiple metabolic syndrome. An epidemiologic perspective. Epidemiol Rev 20:157–172PubMedCrossRef
5.
Zurück zum Zitat Bonora E, Formentini G, Calcaterra F et al (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25(7):1135–1141PubMedCrossRef Bonora E, Formentini G, Calcaterra F et al (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25(7):1135–1141PubMedCrossRef
6.
Zurück zum Zitat Howard G, O’Leary DH, Zaccaro D et al (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93(10):1809–1817PubMedCrossRef Howard G, O’Leary DH, Zaccaro D et al (1996) Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93(10):1809–1817PubMedCrossRef
7.
Zurück zum Zitat Petri M, Spence D, Bone LR, Hochberg MC (1992) Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine Baltimore 71:291–302PubMed Petri M, Spence D, Bone LR, Hochberg MC (1992) Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine Baltimore 71:291–302PubMed
8.
Zurück zum Zitat Petri M, Yoo S-S (1994) Predictors of glucose intolerance in systemic lupus erythematosus [abstract]. Arthritis Rheum 37(Suppl):323 Petri M, Yoo S-S (1994) Predictors of glucose intolerance in systemic lupus erythematosus [abstract]. Arthritis Rheum 37(Suppl):323
9.
Zurück zum Zitat Bruce IN, Urowitz MB, Gladman DD et al (2003) Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 48:3159–3167PubMedCrossRef Bruce IN, Urowitz MB, Gladman DD et al (2003) Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 48:3159–3167PubMedCrossRef
10.
Zurück zum Zitat Sada KE, Yamasaki Y, Maruyama M et al (2006) Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 33(8):1545–1552PubMed Sada KE, Yamasaki Y, Maruyama M et al (2006) Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 33(8):1545–1552PubMed
11.
Zurück zum Zitat Nourooz-zadeh J, Tajaddini-Sarmadi J, McCarthy S et al (1995) Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054–1058PubMedCrossRef Nourooz-zadeh J, Tajaddini-Sarmadi J, McCarthy S et al (1995) Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054–1058PubMedCrossRef
12.
Zurück zum Zitat Berliner JA, Navab M, Fogelman AM et al (1995) Atherosclerosis: basic mechanism of oxidation, inflammation and genetics. Circulation 91:2488–2496PubMedCrossRef Berliner JA, Navab M, Fogelman AM et al (1995) Atherosclerosis: basic mechanism of oxidation, inflammation and genetics. Circulation 91:2488–2496PubMedCrossRef
13.
Zurück zum Zitat Lopez LR, Salazar-Paramo M, Palafox-Sanchez C et al (2006) Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15:80–86PubMedCrossRef Lopez LR, Salazar-Paramo M, Palafox-Sanchez C et al (2006) Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15:80–86PubMedCrossRef
14.
Zurück zum Zitat Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E (2005) The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 1051:442–454PubMedCrossRef Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E (2005) The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 1051:442–454PubMedCrossRef
15.
Zurück zum Zitat Zampieri S, Iaccarino L, Ghirardello A et al (2005) Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 1051:351–361PubMedCrossRef Zampieri S, Iaccarino L, Ghirardello A et al (2005) Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 1051:351–361PubMedCrossRef
16.
Zurück zum Zitat Leuven SI van, Kastelein JJ, D’Cruz DP et al (2006) Atherogenesis in rheumatology. Lupus 15(3):117–121PubMedCrossRef Leuven SI van, Kastelein JJ, D’Cruz DP et al (2006) Atherogenesis in rheumatology. Lupus 15(3):117–121PubMedCrossRef
17.
Zurück zum Zitat Bruce IN (2005) ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44(12):1492–1502 Bruce IN (2005) ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 44(12):1492–1502
18.
Zurück zum Zitat Ryan MJ, McLemore GR, Hendrix ST (2006) Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48(5):988–993PubMedCrossRef Ryan MJ, McLemore GR, Hendrix ST (2006) Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48(5):988–993PubMedCrossRef
19.
Zurück zum Zitat Bellomio V, Spindler A, Lucero E et al (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18(11):1019–1025PubMedCrossRef Bellomio V, Spindler A, Lucero E et al (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18(11):1019–1025PubMedCrossRef
20.
Zurück zum Zitat George J, Harats D, Gilburd B et al (1999) Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 8(3):220–226PubMedCrossRef George J, Harats D, Gilburd B et al (1999) Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 8(3):220–226PubMedCrossRef
21.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef
22.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
23.
Zurück zum Zitat Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef
24.
Zurück zum Zitat Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring the quality of life of cancer patients. J Chron Dis 34:585–597PubMedCrossRef Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring the quality of life of cancer patients. J Chron Dis 34:585–597PubMedCrossRef
25.
Zurück zum Zitat Wolfe F, Michaud K, Pincus T (2004) Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 50:3296–3305PubMedCrossRef Wolfe F, Michaud K, Pincus T (2004) Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 50:3296–3305PubMedCrossRef
26.
Zurück zum Zitat National Cholesterol Education Program (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285:2486–2497 National Cholesterol Education Program (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285:2486–2497
27.
Zurück zum Zitat Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42(1):51–60PubMedCrossRef Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42(1):51–60PubMedCrossRef
28.
Zurück zum Zitat Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP et al (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645–651PubMedCrossRef Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP et al (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645–651PubMedCrossRef
29.
Zurück zum Zitat Medina G, Casaos D, Jara LJ et al (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62(7):607–610PubMedCrossRef Medina G, Casaos D, Jara LJ et al (2003) Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62(7):607–610PubMedCrossRef
30.
Zurück zum Zitat Esdaile JM, Abrahamowicz M, Grodzicky T et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44(10):2331–2337PubMedCrossRef Esdaile JM, Abrahamowicz M, Grodzicky T et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44(10):2331–2337PubMedCrossRef
31.
Zurück zum Zitat Doria A, Shoenfeld Y, Wu R et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62(11):1071–1077PubMedCrossRef Doria A, Shoenfeld Y, Wu R et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62(11):1071–1077PubMedCrossRef
32.
Zurück zum Zitat Chung CP, Avalos I, Oeser A et al (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66(2):208–214PubMedCrossRef Chung CP, Avalos I, Oeser A et al (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66(2):208–214PubMedCrossRef
33.
Zurück zum Zitat Svenungsson E, Jensen-Urstad K, Heimbürger M et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104(16):1887–1893PubMedCrossRef Svenungsson E, Jensen-Urstad K, Heimbürger M et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104(16):1887–1893PubMedCrossRef
34.
Zurück zum Zitat El Magadmi M, Ahmad Y, Turkie W et al (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33(1):50–56 El Magadmi M, Ahmad Y, Turkie W et al (2006) Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 33(1):50–56
35.
Zurück zum Zitat Frostegård J (2002) Autoimmunity: oxidized LDL and cardiovascular disease. Autoimmun Rev 1(4):233–237PubMedCrossRef Frostegård J (2002) Autoimmunity: oxidized LDL and cardiovascular disease. Autoimmun Rev 1(4):233–237PubMedCrossRef
36.
Zurück zum Zitat McMahona M, Hahna BH (2007) Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19(6):633–639CrossRef McMahona M, Hahna BH (2007) Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19(6):633–639CrossRef
Metadaten
Titel
Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus
Effect on carotid intima-media thickness
verfasst von
T.A. Gheita, MD
H.A. Raafat
S. Sayed
H. El-Fishawy
M.M. Nasrallah
E. Abdel-Rasheed
Publikationsdatum
01.03.2013
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 2/2013
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-012-1058-9

Weitere Artikel der Ausgabe 2/2013

Zeitschrift für Rheumatologie 2/2013 Zur Ausgabe

CME Zertifizierte Fortbildung

IgG4-assoziierte Erkrankung

Mitteilungen der DRL

Mitteilungen der DRL

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.